Christine Decanter1, Maeliss Peigne1, Audrey Mailliez2, Franck Morschhauser3, Audrey Dassonneville4, Didier Dewailly1, Pascal Pigny5. 1. Service de Gynécologie Endocrinienne et Médecine de la Reproduction, Hôpital Jeanne de Flandre, Centre Hospitalier Régional Universitaire, Lille, France. 2. Département de sénologie, Centre Oscar Lambret, Lille, France. 3. Service des maladies du sang, Hôpital Huriez, Centre Hospitalier Régional Universitaire, Lille, France. 4. Laboratoire de Biochimie & Hormonologie, Centre de Biologie Pathologie, Centre Hospitalier Régional Universitaire, Lille, France. 5. Laboratoire de Biochimie & Hormonologie, Centre de Biologie Pathologie, Centre Hospitalier Régional Universitaire, Lille, France. Electronic address: pascal.pigny@chru-lille.fr.
Abstract
OBJECTIVE: To evaluate the utility of a hypersensitive assay for measuring low antimüllerian hormone (AMH) levels in young cancer patients during the ovarian recovery phase of their chemotherapy. DESIGN: Retrospective study. SETTING: Academic medical center. PATIENT(S): Fifty-eight samples drawn at least 3 months after the end of chemotherapy in 30 women having either breast cancer (n=13) or hematologic malignancies (n=17) were selected to constitute two equally size groups: amenorrhea (n=30 samples) or spontaneous cycle (n=28 samples). INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Serum AMH levels were measured by a conventional AMH ELISA (EIA AMH/MIS) and a hypersensitive ELISA (PicoAMH, AnshLabs) on the same sample. RESULT(S): Using a conventional assay, serum AMH was detectable (≥3 pmol/L) in 6.7% and in 10.7% of the samples corresponding to amenorrheic or cycling patients, respectively (nonsignificant). By contrast, with PicoAMH, serum AMH was detectable (≥0.07 pmol/L) in 71.4% of the samples from cycling women vs. 16.7% of the samples from amenorrheic patients. Multivariate regression analysis showed that among putative contributors, only the menstrual status (r=0.307) and serum FSH level (r=-0.546) were independently correlated to a detectable serum AMH with the picoAMH assay exclusively. CONCLUSION(S): The picoAMH assay, allowing measurement of very low AMH concentrations in human serum, should refine postchemotherapy ovarian follow-up in young women.
OBJECTIVE: To evaluate the utility of a hypersensitive assay for measuring low antimüllerian hormone (AMH) levels in young cancerpatients during the ovarian recovery phase of their chemotherapy. DESIGN: Retrospective study. SETTING: Academic medical center. PATIENT(S): Fifty-eight samples drawn at least 3 months after the end of chemotherapy in 30 women having either breast cancer (n=13) or hematologic malignancies (n=17) were selected to constitute two equally size groups: amenorrhea (n=30 samples) or spontaneous cycle (n=28 samples). INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Serum AMH levels were measured by a conventional AMH ELISA (EIA AMH/MIS) and a hypersensitive ELISA (PicoAMH, AnshLabs) on the same sample. RESULT(S): Using a conventional assay, serum AMH was detectable (≥3 pmol/L) in 6.7% and in 10.7% of the samples corresponding to amenorrheic or cycling patients, respectively (nonsignificant). By contrast, with PicoAMH, serum AMH was detectable (≥0.07 pmol/L) in 71.4% of the samples from cycling women vs. 16.7% of the samples from amenorrheic patients. Multivariate regression analysis showed that among putative contributors, only the menstrual status (r=0.307) and serum FSH level (r=-0.546) were independently correlated to a detectable serum AMH with the picoAMH assay exclusively. CONCLUSION(S): The picoAMH assay, allowing measurement of very low AMH concentrations in human serum, should refine postchemotherapy ovarian follow-up in young women.
Authors: Emily R Garnett; Purviben Jariwala; Kesha Rector; William E Gibbons; Paul W Zarutskie; Sridevi Devaraj Journal: Pract Lab Med Date: 2019-09-27
Authors: Richard A Anderson; Rachel Remedios; Amy A Kirkwood; Pip Patrick; Linsey Stevens; Laura Clifton-Hadley; Tom Roberts; Chris Hatton; Nagesh Kalakonda; Don W Milligan; Pam McKay; Clare Rowntree; Fiona M Scott; Peter W M Johnson Journal: Lancet Oncol Date: 2018-09-13 Impact factor: 54.433